For the Inventor, By the Inventor

Enter inventor name

Martin E Gleave

Vancouver, Canada

Martin E Gleave

USPTO Granted Patents = 54 (Patent Applications = 9)

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 11)

Average Co-Inventor Count = 2.9

ph-index = 8

Forward Citations = 274(Granted Patents)

Forward Citations (Not Self Cited) = 161(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

The University of British Columbia

Centre for Drug Research and Development

Teva Pharmaceutical Industries Limited

4. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

B1SP Fusion Protein

Mucoadhesive Drug Delivery

Polymeric Paste Compositions

Antisense Oligonucleotides

Cancer Treatment

HSP27 Inhibitors

RNAi Probes

Clusterin Antisense Therapy

TRPM-2 Antisense Therapy

Castration-Resistant Prostate Cancer

Bispecific Oligonucleotides

Hyperbranched Polyglycerols

54 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378301 - B1SP fusion protein therapeutics, methods, and uses (2025-08-05),

2. 12171833 - Mucoadhesive polymeric drug delivery compositions and methods (2024-12-24),

3. 11167034 - Polymeric paste compositions for drug delivery (2021-11-09),

4. 11142561 - B1SP fusion protein therapeutics, methods, and uses (2021-10-12),

5. 10525131 - Derivatized hyperbranched polyglycerols (2020-01-07),

6. 10071160 - Derivatized hyperbranched polyglycerols (2018-09-11),

7. 9790500 - Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer (2017-10-17),

8. 9717792 - Combination therapy for cancer using HSP27 inhibitor and EGFR tyrosine kinase inhibitors or anti-folates (2017-08-01),

9. 9580712 - Compositions and methods for treatment of prostate and other cancers (2017-02-28),

10. 9561278 - Derivatized hyperbranched polyglycerols (2017-02-07),

11. 9487777 - RNAi probes targeting cancer-related proteins (2016-11-08),

12. 9457045 - Combination of anti-clusterin oligonucleotide with Hsp90 inhibitor for the treatment of prostate cancer (2016-10-04),

13. 9404109 - Compositions and methods for treatment of prostate and other cancers (2016-08-02),

14. 9205102 - Method for treatment of castration-resistant prostate cancer (2015-12-08),

15. 9200285 - Clusterin antisense therapy for treatment of cancer (2015-12-01),

Title: Martin E Gleave - Innovator from Vancouver, CA

Introduction: Martin E Gleave is a renowned inventor based in Vancouver, Canada, known for his groundbreaking contributions to the field of medical research and biotechnology.

Latest Patents: Martin E Gleave holds several patents in the areas of cancer treatment, precision medicine, and drug development, showcasing his innovative approach to addressing complex medical challenges.

Career Highlights: With a distinguished career spanning over three decades, Martin E Gleave has held key positions in leading research institutions and biotech companies, where he has spearheaded numerous projects that have significantly impacted the healthcare industry.

Collaborations: Throughout his career, Martin E Gleave has collaborated with top scientists, medical professionals, and pharmaceutical companies to advance the development of novel therapies and diagnostic tools, fostering a culture of innovation and excellence in the field.

Conclusion: Martin E Gleave's relentless pursuit of innovation and his commitment to improving patient outcomes have solidified his reputation as a visionary inventor in the realm of medical research and biotechnology.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…